Clinical Trials Logo

Predicted Tauopathies, Including clinical trials

View clinical trials related to Predicted Tauopathies, Including.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT01056965 Completed - Clinical trials for Progressive Supranuclear Palsy

Davunetide (AL-108) in Predicted Tauopathies - Pilot Study

Start date: January 2010
Phase: Phase 1
Study type: Interventional

The primary objective of the study is to obtain preliminary safety and tolerability data with davunetide (NAP, AL-108) in patients with a tauopathy (frontotemporal lobar degeneration [FTLD] with predicted tau pathology, corticobasal degeneration syndrome [CBS] or progressive supranuclear palsy [PSP]). The secondary objectives of this study are to obtain preliminary data on short term changes (at 12 weeks) in a variety of clinical, functional and biomarker measurements from baseline, including cerebrospinal fluid (CSF) tau levels, eye movements, and brain MRI measurements.